دورية أكاديمية
Immunohematologic Biomarkers in COVID-19: Insights into Pathogenesis, Prognosis, and Prevention.
| العنوان: | Immunohematologic Biomarkers in COVID-19: Insights into Pathogenesis, Prognosis, and Prevention. |
|---|---|
| المؤلفون: | Sweet DR; Case Western Reserve University School of Medicine, Cleveland, OH., Freeman ML; Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, Cleveland, OH., Zidar DA; Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH.; Cardiology Section, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH.; Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Case Western Reserve University, Cleveland, OH. |
| المصدر: | Pathogens & immunity [Pathog Immun] 2023 Jun 26; Vol. 8 (1), pp. 17-50. Date of Electronic Publication: 2023 Jun 26 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Case Western Reserve University Country of Publication: United States NLM ID: 101683909 Publication Model: eCollection Cited Medium: Internet ISSN: 2469-2964 (Electronic) Linking ISSN: 24692964 NLM ISO Abbreviation: Pathog Immun Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Cleveland, OH : Case Western Reserve University, [2016]- |
| مستخلص: | Coronavirus disease 2019 (COVID-19) has had profound effects on the health of individuals and on healthcare systems worldwide. While healthcare workers on the frontlines have fought to quell multiple waves of infection, the efforts of the larger research community have changed the arch of this pandemic as well. This review will focus on biomarker discovery and other efforts to identify features that predict outcomes, and in so doing, identify possible effector and passenger mechanisms of adverse outcomes. Identifying measurable soluble factors, cell-types, and clinical parameters that predict a patient's disease course will have a legacy for the study of immunologic responses, especially stimuli, which induce an overactive, yet ineffectual immune system. As prognostic biomarkers were identified, some have served to represent pathways of therapeutic interest in clinical trials. The pandemic conditions have created urgency for accelerated target identification and validation. Collectively, these COVID-19 studies of biomarkers, disease outcomes, and therapeutic efficacy have revealed that immunologic systems and responses to stimuli are more heterogeneous than previously assumed. Understanding the genetic and acquired features that mediate divergent immunologic outcomes in response to this global exposure is ongoing and will ultimately improve our preparedness for future pandemics, as well as impact preventive approaches to other immunologic diseases. Competing Interests: The authors report no competing financial interests (Copyright © 2023 Pathogens and Immunity.) |
| References: | Biomark Insights. 2022 Jun 16;17:11772719221106600. (PMID: 35747885) Aging (Albany NY). 2020 Jul 30;12(14):13849-13859. (PMID: 32730223) J Natl Cancer Inst. 2014 May 29;106(6):dju124. (PMID: 24875653) N Engl J Med. 2021 Apr 22;384(16):1491-1502. (PMID: 33631065) Commun Biol. 2023 Jan 20;6(1):76. (PMID: 36670287) Nature. 2021 Jul;595(7866):283-288. (PMID: 34010947) Viruses. 2021 Sep 20;13(9):. (PMID: 34578457) Biomedicines. 2022 Feb 03;10(2):. (PMID: 35203578) Autoimmun Rev. 2022 Dec;21(12):103206. (PMID: 36195247) Science. 2021 Oct 08;374(6564):eabh1823. (PMID: 34465633) Cytokine Growth Factor Rev. 2020 Jun;53:13-24. (PMID: 32475759) Lancet. 2020 May 30;395(10238):1695-1704. (PMID: 32401715) Sci Adv. 2022 Oct 7;8(40):eabn3777. (PMID: 36206332) Infect Dis Ther. 2022 Jun;11(3):953-972. (PMID: 35445964) J Infect Dis. 2021 Dec 1;224(11):1861-1872. (PMID: 34718664) J Investig Med. 2022 Feb;70(2):415-420. (PMID: 34620707) BMC Infect Dis. 2021 Jan 18;21(1):80. (PMID: 33461497) Nature. 2022 Jul;607(7917):97-103. (PMID: 35255492) Future Sci OA. 2021 Apr 20;7(7):FSO712. (PMID: 34254030) Virol J. 2022 Jun 8;19(1):101. (PMID: 35676707) J Intensive Care Med. 2022 Sep;37(9):1152-1158. (PMID: 34791940) Immunity. 2021 Jul 13;54(7):1578-1593.e5. (PMID: 34051147) Int Immunopharmacol. 2022 Oct;111:109075. (PMID: 35905562) Clin Chim Acta. 2020 Jul;506:145-148. (PMID: 32178975) Int J Gen Med. 2021 Sep 11;14:5517-5526. (PMID: 34539185) Cell Rep. 2021 Dec 28;37(13):110169. (PMID: 34932974) JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570) Ann Transl Med. 2020 Oct;8(19):1230. (PMID: 33178762) Pneumonia (Nathan). 2022 Nov 25;14(1):8. (PMID: 36424653) Nat Med. 2022 Jan;28(1):39-50. (PMID: 35064248) Nat Med. 2021 May;27(5):904-916. (PMID: 33879890) Front Immunol. 2021 May 03;12:659018. (PMID: 34012444) Lancet. 2021 May 01;397(10285):1637-1645. (PMID: 33933206) N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013) Gut Pathog. 2022 Aug 9;14(1):34. (PMID: 35945626) BMC Infect Dis. 2021 Jun 14;21(1):574. (PMID: 34126954) Lancet Respir Med. 2021 Dec;9(12):1365-1376. (PMID: 34672949) Cytometry A. 2023 Feb;103(2):127-135. (PMID: 34125495) J Infect. 2021 Jan;82(1):e19-e21. (PMID: 32871180) Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076) Infect Dis Ther. 2022 Feb;11(1):231-248. (PMID: 34757578) Comput Biol Med. 2022 Jun;145:105467. (PMID: 35378436) Pathog Immun. 2020 Oct 2;5(1):312-326. (PMID: 33089037) Front Radiol. 2022;2:. (PMID: 36437821) Cell. 2022 Mar 17;185(6):1025-1040.e14. (PMID: 35148837) JAMA. 2020 Apr 28;323(16):1612-1614. (PMID: 32191259) Nat Rev Immunol. 2022 Aug;22(8):484-498. (PMID: 34815556) FEBS J. 2021 Sep;288(17):5190-5200. (PMID: 33098359) EBioMedicine. 2022 Nov;85:104299. (PMID: 36209522) J Immunol. 2021 Jun 15;206(12):2785-2790. (PMID: 34049971) Cell Host Microbe. 2022 Jan 12;30(1):83-96.e4. (PMID: 34965382) EClinicalMedicine. 2022 Jul;49:101495. (PMID: 35702332) BMJ Evid Based Med. 2021 Jun;26(3):107-108. (PMID: 32934000) Cell. 2020 Oct 1;183(1):143-157.e13. (PMID: 32877699) Curr Opin Rheumatol. 2007 Nov;19(6):636-43. (PMID: 17917546) Cell. 2021 Apr 1;184(7):1895-1913.e19. (PMID: 33657410) Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2200413119. (PMID: 35576468) Nat Immunol. 2021 Mar;22(3):322-335. (PMID: 33531712) APMIS. 2017 Oct;125(10):863-871. (PMID: 28766758) PLoS Genet. 2022 Apr 28;18(4):e1010113. (PMID: 35482673) Lancet Respir Med. 2021 Dec;9(12):1407-1418. (PMID: 34480861) Blood. 2012 Nov 29;120(23):4599-608. (PMID: 23065151) J Med Virol. 2022 Nov;94(11):5103-5111. (PMID: 35819034) Intensive Care Med. 2020 May;46(5):846-848. (PMID: 32125452) Nat Immunol. 2020 Dec;21(12):1506-1516. (PMID: 33028979) PLoS One. 2021 Jun 29;16(6):e0253894. (PMID: 34185801) Cell Rep Med. 2022 Jun 21;3(6):100663. (PMID: 35732153) Immun Inflamm Dis. 2022 Apr;10(4):e597. (PMID: 35349757) J Transl Med. 2022 Mar 16;20(1):129. (PMID: 35296346) J Clin Med. 2020 Jul 29;9(8):. (PMID: 32751400) Nat Med. 2021 Oct;27(10):1752-1760. (PMID: 34480127) J Investig Med. 2021 Mar;69(3):710-718. (PMID: 33431604) PLoS Pathog. 2021 Sep 2;17(9):e1009850. (PMID: 34473802) EBioMedicine. 2020 Nov;61:103026. (PMID: 33039714) J Am Coll Cardiol. 2017 Apr 18;69(15):1952-1967. (PMID: 28408026) Nature. 2022 Nov;611(7934):139-147. (PMID: 36044993) Lancet Respir Med. 2021 Aug;9(8):924-932. (PMID: 34051877) JAMA Netw Open. 2022 May 2;5(5):e2213253. (PMID: 35604688) JCI Insight. 2021 Aug 9;6(15):. (PMID: 34166229) Cytokine Growth Factor Rev. 2022 Feb;63:34-43. (PMID: 35115233) Sci Rep. 2022 Jun 9;12(1):9502. (PMID: 35681070) Ann Rheum Dis. 2022 Dec;81(12):1695-1703. (PMID: 35973806) Nature. 2021 Mar;591(7848):92-98. (PMID: 33307546) JAMA Netw Open. 2021 Nov 1;4(11):e2134147. (PMID: 34762110) Front Immunol. 2022 Apr 11;13:866153. (PMID: 35479062) Exp Hematol Oncol. 2020 Jul 17;9:16. (PMID: 32695551) Science. 2020 Oct 23;370(6515):. (PMID: 32972996) Clin Nutr ESPEN. 2021 Oct;45:120-126. (PMID: 34620307) N Engl J Med. 2021 Mar 4;384(9):795-807. (PMID: 33306283) Sci Rep. 2021 Apr 13;11(1):8059. (PMID: 33850184) Science. 2020 Sep 4;369(6508):. (PMID: 32669297) Int Immunopharmacol. 2020 Nov;88:106903. (PMID: 32862111) Expert Rev Cardiovasc Ther. 2016;14(5):573-7. (PMID: 26878164) EBioMedicine. 2020 Jul;57:102885. (PMID: 32650275) Science. 2020 Oct 2;370(6512):89-94. (PMID: 32753554) Ann Rheum Dis. 2020 Dec;79(12):1661-1663. (PMID: 32581086) J Cell Mol Med. 2022 May;26(10):3022-3030. (PMID: 35419946) Signal Transduct Target Ther. 2020 Mar 27;5(1):33. (PMID: 32296069) BMC Infect Dis. 2021 Sep 8;21(1):931. (PMID: 34496794) Am J Hematol. 2020 Jun;95(6):E131-E134. (PMID: 32129508) Lancet Rheumatol. 2021 Dec;3(12):e829-e831. (PMID: 34746843) Nature. 2023 Nov;623(7985):139-148. (PMID: 37748514) Clin Chim Acta. 2020 Oct;509:235-243. (PMID: 32533986) Epidemiol Infect. 2021 Jul 02;149:e162. (PMID: 34210368) Clin Exp Immunol. 2020 Jul;201(1):76-84. (PMID: 32365221) Open Forum Infect Dis. 2020 Dec 28;8(2):ofaa638. (PMID: 33553477) Nature. 2021 Dec;600(7889):472-477. (PMID: 34237774) Open Forum Infect Dis. 2023 Feb 04;10(2):ofad063. (PMID: 36861088) Cell. 2022 Mar 3;185(5):881-895.e20. (PMID: 35216672) Nat Med. 2020 Jul;26(7):1070-1076. (PMID: 32514174) EBioMedicine. 2021 May;67:103378. (PMID: 34000622) Int J Epidemiol. 2022 Oct 13;51(5):1384-1395. (PMID: 35770811) Front Public Health. 2021 Jul 05;9:691163. (PMID: 34291031) Int J Infect Dis. 2021 Apr;105:668-674. (PMID: 33737133) Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264) EBioMedicine. 2022 Nov;85:104315. (PMID: 36309007) Stem Cell Reports. 2017 Feb 14;8(2):346-359. (PMID: 28111277) Intensive Care Med. 2021 Jun;47(6):704-706. (PMID: 33835207) Sci Transl Med. 2020 Nov 18;12(570):. (PMID: 33139519) Sci Immunol. 2020 Jul 15;5(49):. (PMID: 32669287) Ann Rheum Dis. 2021 Sep;80(9):1105-1107. (PMID: 34340980) MMWR Morb Mortal Wkly Rep. 2021 Apr 09;70(14):519-522. (PMID: 33830988) J Exp Med. 2021 Jul 5;218(7):. (PMID: 33890986) Exp Ther Med. 2021 May;21(5):449. (PMID: 33747184) Nat Rev Immunol. 2020 Oct;20(10):585-586. (PMID: 32788708) Am J Kidney Dis. 2022 Feb;79(2):257-267.e1. (PMID: 34710516) Nat Immunol. 2022 May;23(5):781-790. (PMID: 35383307) Cell Syst. 2020 Jul 22;11(1):11-24.e4. (PMID: 32619549) Cell. 2020 Sep 17;182(6):1419-1440.e23. (PMID: 32810438) J Pers Med. 2022 Oct 02;12(10):. (PMID: 36294770) Rheumatol Int. 2022 Sep;42(9):1523-1530. (PMID: 35650445) J Med Virol. 2020 Sep;92(9):1533-1541. (PMID: 32181903) Sci Rep. 2021 Sep 9;11(1):17885. (PMID: 34504246) Cell. 2020 Sep 17;182(6):1401-1418.e18. (PMID: 32810439) J Exp Med. 2020 Dec 7;217(12):. (PMID: 32886755) JAMA Intern Med. 2020 Jul 1;180(7):934-943. (PMID: 32167524) Cell Syst. 2021 Aug 18;12(8):780-794.e7. (PMID: 34139154) Clin Interv Aging. 2013;8:1489-96. (PMID: 24235821) Int J Environ Res Public Health. 2023 Feb 08;20(4):. (PMID: 36833680) Int J Infect Dis. 2022 Sep;122:976-978. (PMID: 35872097) J Infect Dis. 2022 Aug 26;226(3):463-473. (PMID: 35134186) Int J Infect Dis. 2022 Mar;116:74-79. (PMID: 34952211) Lancet Rheumatol. 2021 Oct;3(10):e690-e697. (PMID: 34396156) Sci Rep. 2021 May 25;11(1):10902. (PMID: 34035353) Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143) Chin Med J (Engl). 2020 Jun 5;133(11):1261-1267. (PMID: 32209890) J Med Virol. 2022 Mar;94(3):844-846. (PMID: 34750829) Prev Chronic Dis. 2021 Jul 01;18:E66. (PMID: 34197283) Blood Transfus. 2021 Jan;19(1):34-36. (PMID: 32955421) Sci Rep. 2021 Jun 2;11(1):11591. (PMID: 34078950) BMJ Glob Health. 2021 Dec;6(12):. (PMID: 34916273) Sci Immunol. 2021 Aug 19;6(62):. (PMID: 34413139) Cell. 2020 Jul 9;182(1):59-72.e15. (PMID: 32492406) PLoS One. 2022 Oct 25;17(10):e0273134. (PMID: 36282812) JAMA Netw Open. 2021 Dec 1;4(12):e2141328. (PMID: 34964849) PLoS One. 2022 May 25;17(5):e0268530. (PMID: 35613127) Am J Emerg Med. 2022 Jun;56:329-331. (PMID: 34509327) N Engl J Med. 2021 Apr 22;384(16):1503-1516. (PMID: 33631066) mSphere. 2020 Oct 7;5(5):. (PMID: 33028689) Nat Commun. 2021 Sep 14;12(1):5417. (PMID: 34521836) Front Immunol. 2020 Dec 03;11:611004. (PMID: 33343585) Clin Immunol. 2020 Aug;217:108486. (PMID: 32479985) RMD Open. 2021 May;7(2):. (PMID: 33958439) Front Med (Lausanne). 2022 Feb 21;9:837411. (PMID: 35265643) Crit Care. 2021 Dec 6;25(1):417. (PMID: 34872611) Eur Respir J. 2023 Jan 12;61(1):. (PMID: 36137590) Sci Immunol. 2020 Sep 28;5(51):. (PMID: 32989174) Antimicrob Agents Chemother. 2020 Aug 20;64(9):. (PMID: 32661006) iScience. 2021 Nov 19;24(11):103325. (PMID: 34723157) Int Arch Allergy Immunol. 2021;182(3):254-262. (PMID: 33498051) Nat Immunol. 2020 Sep;21(9):1107-1118. (PMID: 32788748) Immunother Adv. 2021 Jul 02;1(1):ltab015. (PMID: 35965490) JAMA. 2021 Aug 10;326(6):499-518. (PMID: 34228774) |
| فهرسة مساهمة: | Keywords: COVID-19; SARS-CoV-2; biomarkers; immunophenotyping; multiomics; prevention |
| تواريخ الأحداث: | Date Created: 20230710 Latest Revision: 20231106 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC10324469 |
| DOI: | 10.20411/pai.v8i1.572 |
| PMID: | 37427016 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2469-2964 |
|---|---|
| DOI: | 10.20411/pai.v8i1.572 |